153 related articles for article (PubMed ID: 34828466)
1. Handling Uncertainty in Cost-Effectiveness Analysis: Budget Impact and Risk Aversion.
Sendi P; Matter-Walstra K; Schwenkglenks M
Healthcare (Basel); 2021 Oct; 9(11):. PubMed ID: 34828466
[TBL] [Abstract][Full Text] [Related]
2. Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve.
Sendi P
Pharmacoeconomics; 2021 Feb; 39(2):161-169. PubMed ID: 33128734
[TBL] [Abstract][Full Text] [Related]
3. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
[TBL] [Abstract][Full Text] [Related]
4. Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison.
Wolff HB; Qendri V; Kunst N; Alarid-Escudero F; Coupé VMH
Med Decis Making; 2022 Oct; 42(7):956-968. PubMed ID: 35587181
[TBL] [Abstract][Full Text] [Related]
5. The augmented representation of the cost-effectiveness acceptability curve for economic evaluation of health technology.
Araki D; Kamae I
Kobe J Med Sci; 2015 Mar; 61(1):E9-18. PubMed ID: 25868612
[TBL] [Abstract][Full Text] [Related]
6. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.
Fenwick E; Marshall DA; Levy AR; Nichol G
BMC Health Serv Res; 2006 Apr; 6():52. PubMed ID: 16623946
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness and affordability of strategy for preventing mother-to-child transmission of hepatitis B in China].
Lin Y; Zhang SX; Yang PC; Cai YL; Zou YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):852-859. PubMed ID: 28738455
[No Abstract] [Full Text] [Related]
8. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane.
Sendi PP; Briggs AH
Health Econ; 2001 Oct; 10(7):675-80. PubMed ID: 11747050
[TBL] [Abstract][Full Text] [Related]
9. Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches.
Elbasha EH
Pharmacoeconomics; 2022 May; 40(5):497-507. PubMed ID: 35137340
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.
Fenwick E; O'Brien BJ; Briggs A
Health Econ; 2004 May; 13(5):405-15. PubMed ID: 15127421
[TBL] [Abstract][Full Text] [Related]
11. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
Raphael J; Helou J; Pritchard KI; Naimark DM
Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
[TBL] [Abstract][Full Text] [Related]
12. Incorporating Portfolio Uncertainty in Decision Rules for Healthcare Resource Allocation.
Sendi P; Gafni A; Birch S; Walter SD
Healthcare (Basel); 2021 Mar; 9(3):. PubMed ID: 33799361
[TBL] [Abstract][Full Text] [Related]
13. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).
Barton GR; Briggs AH; Fenwick EA
Value Health; 2008; 11(5):886-97. PubMed ID: 18489513
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness acceptability curves revisited.
Al MJ
Pharmacoeconomics; 2013 Feb; 31(2):93-100. PubMed ID: 23329426
[TBL] [Abstract][Full Text] [Related]
15. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost-Effectiveness Affordability Curves in Health Care Decision Making.
Tu HAT; de Vries R; Woerdenbag HJ; Li SC; Le HH; van Hulst M; Postma MJ
Value Health Reg Issues; 2012 May; 1(1):7-14. PubMed ID: 29702830
[TBL] [Abstract][Full Text] [Related]
17. Real-World Cost-Effectiveness Analysis: How Much Uncertainty Is in the Results?
Barr HK; Guggenbickler AM; Hoch JS; Dewa CS
Curr Oncol; 2023 Apr; 30(4):4078-4093. PubMed ID: 37185423
[TBL] [Abstract][Full Text] [Related]
18. Increasing the impact of budget impact analysis: incorporating uncertainty for decision-makers in small markets.
Hofmeister M; Clement F
Int J Technol Assess Health Care; 2022 Jan; 38(1):e15. PubMed ID: 35080195
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
